Advertisement

Drugs Used in Narcolepsy and Other Hypersomnias

  • Gert Jan Lammers
    Correspondence
    Department of Neurology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 AA, the Netherlands.
    Affiliations
    Department of Neurology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 AA, the Netherlands

    Sleep-Wake Centers of Stichting Epilepsie Instellingen Nedereland (SEIN), Achterweg 5, Heemstede 2103 SW, the Netherlands
    Search for articles by this author
Published:September 01, 2022DOI:https://doi.org/10.1016/j.jsmc.2022.06.005

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American Academy of Sleep Medicine
        The international classification of sleep disorders.
        3rd edition. American Academy of Sleep Medicine, Darien (IL)2014
        • Overeem S.
        • Mignot E.
        • van Dijk J.G.
        • et al.
        Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives.
        J Clin Neurophysiol. 2001; 18: 78-105
        • Ruoff C.M.
        • Reaven N.L.
        • Funk S.E.
        • et al.
        High rates of psychiatric comorbidity in narcolepsy: findings from the burden of narcolepsy disease (BOND) study of 9,312 patients in the United States.
        J Clin Psychiatry. 2017; 78: 171-176
        • Postiglione E.
        • Antelmi E.
        • Pizza F.
        • et al.
        The clinical spectrum of childhood narcolepsy.
        Sleep Med Rev. 2018; 38: 70-85
        • Silber M.H.
        • Krahn L.E.
        • Olson E.
        • et al.
        The epidemi- ology of narcolepsy in Olmsted County, Minnesota: a population-based study.
        Sleep. 2002; 25: 197-202
        • Longstreth W.T.
        • Koepsell T.D.
        • Ton T.G.
        • et al.
        The epidemiology of narcolepsy.
        Sleep. 2007; 30: 13-26
        • Wijnans L.
        • Lecomte C.
        • de Vries C.
        • et al.
        The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1) pandemic and vaccination campaigns.
        Vaccine. 2013; 31: 1246-1254
        • Mullington J.
        • Broughton R.
        Scheduled naps in the management of daytime sleepiness in narcolepsy- cataplexy.
        Sleep. 1993; 16: 444-456
        • Bruck D.
        • Armstrong S.
        • Coleman G.
        Sleepiness after glucose in narcolepsy.
        J Sleep Res. 1994; 3: 171-179
        • Wise M.S.
        • Arand D.L.
        • Auger R.R.
        • et al.
        Treatment of narcolepsy and other hypersomnias of central origin.
        Sleep. 2007; 30: 1712-1727
        • M Billiard
        • C Bassetti
        • Y Dauvilliers
        • et al.
        EFNS guidelines on management of narcolepsy.
        Eur J Neurol. 2006; 13: 1035-1048
        • Parkes J.D.
        • Dahlitz M.
        Amphetamine prescription.
        Sleep. 1993; 16: 201-203
        • Mitler M.M.
        • Aldrich M.S.
        • Koob G.F.
        • et al.
        Narcolepsy and its treatment with stimulants. ASDA standards of practice.
        Sleep. 1994; 17: 352-371
        • Ryan D.H.
        • Bray G.A.
        • Helmcke F.
        • et al.
        Serial echocardiography and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
        Obes Res. 1999; 7: 313-322
      1. (Available at:) (Accessed March 26, 2018)
        • Lopez R.
        • Arnulf I.
        • Drouot X.
        • et al.
        French consensus. Management of patients with hypersomnia: which strategy?.
        Rev Neurol (Paris). 2017; 173: 8-18
        • Evangelista E.
        • Lopez R.
        • Dauvilliers Y.
        Update on treatment for idiopathic hypersomnia.
        Expert Opin Investig Drugs. 2018; 27: 187-192
        • Mayer G.
        • Benes H.
        • Young P.
        • et al.
        Modafinil in the treatment of idiopathic hypersomnia without long sleep time—a randomized, double-blind, placebo- controlled study.
        J Sleep Res. 2015; 24: 74-81
        • Dauvilliers Y.
        • Bassetti C.
        • Lammers G.J.
        • et al.
        • HAR- MONY I study group
        Pitolisant versus placebo or modafinil in patients with narcolepsy: a double- blind, randomised trial.
        Lancet Neurol. 2013; 12: 1068-1075
        • Szakacs Z.
        • Dauvilliers Y.
        • Mikhaylov V.
        • et al.
        • HAR- MONY-CTP study group
        Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
        Lancet Neurol. 2017; 16: 200-207
        • Leu-Semenescu S.
        • Nittur N.
        • Golmard J.-L.
        • et al.
        Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review.
        Sleep Med. 2014; 15: 681-687
        • Black J.
        • Pardi D.
        • Hornfeldt C.S.
        • et al.
        The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo- controlled study in patients with narcolepsy.
        J Clin Sleep Med. 2010; 6: 596-602
        • U.S. Xyrem Multicenter Study Group
        Sodium oxy- bate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy.
        Sleep Med. 2004; 5: 119-123
        • Black J.
        • Houghton W.C.
        Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
        Sleep. 2006; 29: 939-946
        • Schinkelshoek M.S.
        • Smolders I.M.
        • Donjacour C.E.
        • et al.
        Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1.
        J Sleep Res. 2019; 28 ([Epub ahead of print])
        • Feldman N.T.
        Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing.
        Sleep Breath. 2010; 14: 77-79
        • Leu-Semenescu S.
        • Louis P.
        • Arnulf I.
        Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review.
        Sleep Med. 2016; 17: 38-44
        • Brown M.A.
        • Guilleminault C.
        A review of sodium oxy bate and baclofen in the treatment of sleep disorders.
        Curr Pharm Des. 2011; 17: 1430-1435
        • Trotti L.M.
        • Saini P.
        • Koola C.
        • et al.
        Flumazenil for the treatment of refractory hypersomnolence: clinical experience with 153 patients.
        J Clin Sleep Med. 2016; 12: 1389-1394
        • Ruoff C.
        • Swick T.J.
        • Doekel R.
        • et al.
        Effect of oral JZP- 110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study.
        Sleep. 2016; 39: 1379-1387
        • Duchene A.
        • Perier M.
        • Zhao Y.
        • et al.
        Impact of astroglial connexins on modafinil pharmacological properties.
        Sleep. 2016; 39: 1283-1292